Abstract
Cancer is the second highest cause of death globally, with about 70% of deaths occurring in low- or middle-income countries, thus calling for efficient cures. Nanotechnology research has evidenced numerous therapeutic innovations that target the tumor tissues either passively or actively. Camptothecin is a potent anticancer drug which has shown appreciable antitumor activity against a broad spectrum of cancers such as breast, ovarian, colon, lung and stomach. Nonetheless, applications of camptothecin are limited by water insolubility, rapid conversion of its bioactive lactone form to inactive carboxylate under physiological conditions, drug resistance and off-target side effects. Here, we review the delivery of camptothecin by active and passive targeting for anticancer activity. We discuss the mechanism of action and the novel targeted drug delivery platforms that have been explored for the delivery of camptothecin for the treatment of solid tumors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- ERP:
-
Enhanced permeation and retention effect
- Topo-I:
-
Deoxyribonucleic acid topoisomerase I
- SUMO:
-
Small ubiquitin-like modifier
- TCR:
-
Transcription coupled repair
- TDP 1:
-
Tyrosyl-deoxyribonucleic acid phosphodiesterase
- BALB/c:
-
Bagg albino
- Β-GP:
-
Glycerol-2-phosphate
- RIF-l:
-
Radiation-induced fibrosarcoma-1
- HeLa:
-
Human cervical cell line
- VEGF:
-
Vascular endothelial growth factor
- MTT:
-
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- SMNs:
-
Small molecular nanodrugs
- LHRH:
-
Luteinizing hormone-releasing hormone
- BH3:
-
BCL-2 homology 3
- FR:
-
Folate receptor
- PFC:
-
Perfluorocarbon
- ADV:
-
Acoustic droplet vaporization
- US:
-
Ultrasound
- MSNs:
-
Mesoporous silica nanoparticles
- CdS:
-
Cadmium sulfide
- HCN:
-
Herceptin-functionalized camptothecin nanoparticle
- HER2:
-
Human epidermal growth factor receptor 2
- PDSG:
-
Poly[2-(pyridin-2-yldisulfanyl)]-graft-poly(ethylene glycol)
References
Avemann K, Knippers R, Koller T, Sogo J (1988) Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. Mol Cell Biol 8:3026–3034. https://doi.org/10.1128/mcb.8.8.3026
Bahadur KCR, Chandrashekaran V, Cheng B, Chen H, Peña M, Zhang J et al (2014) Redox potential ultrasensitive nanoparticle for the targeted delivery of camptothecin to HER2-positive cancer cells. Mol Pharm 11:1897–1905. https://doi.org/10.1021/mp5000482
Bates D, Harper S (2002) Regulation of vascular permeability by vascular endothelial growth factors. Vasc Pharmacol 39:225–237. https://doi.org/10.1016/s1537-1891(03)00011-9
Berrada M, Serreqi A, Dabbarh F, Owusu A, Gupta A, Lehnert S (2005) A novel non-toxic camptothecin formulation for cancer chemotherapy. Biomaterials 26:2115–2120. https://doi.org/10.1016/j.biomaterials.2004.06.013
Bray F, Jemal A, Grey N, Ferlay J, Forman D (2012) Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. Lancet Oncol 13:790–801. https://doi.org/10.1016/s1470-2045(12)70211-5
Chen W, Kang S, Lin J, Wang C, Chen R, Yeh C (2015) Targeted tumor theranostics using folate-conjugated and camptothecin-loaded acoustic nanodroplets in a mouse xenograft model. Biomaterials 53:699–708. https://doi.org/10.1016/j.biomaterials.2015.02.122
Çırpanlı Y, Allard E, Passirani C, Bilensoy E, Lemaire L, Çalış S, Benoit J (2011) Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model. Int J Pharm 403:201–206. https://doi.org/10.1016/j.ijpharm.2010.10.015
D’Arpa P, Liu L (1995) Cell cycle-specific and transcription-related phosphorylation of mammalian topoisomerase I. Exp Cell Reticuloendothel Syst 217:125–131. https://doi.org/10.1006/excr.1995.1071
Dauty E, Remy J, Zuber G, Behr J (2002) Intracellular delivery of nanometric DNA particles via the folate receptor. Bioconjug Chem 13:831–839. https://doi.org/10.1021/bc0255182
Davis M, Chen Z, Shin D (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7:771–782. https://doi.org/10.1038/nrd2614
Dharap S (2003) Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides. J Control Release 91:61–73. https://doi.org/10.1016/s0168-3659(03)00209-8
Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917. https://doi.org/10.1002/ijc.25516
Galvin P, Thompson D, Ryan K, McCarthy A, Moore A, Burke C et al (2011) Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications. Cell Mol Life Sci 69:389–404. https://doi.org/10.1007/s00018-011-0856-6
Gaur S, Wang Y, Kretzner L, Chen L, Yen T, Wu X et al (2014) Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer. Nanomed Nanotechnol 10:1477–1486. https://doi.org/10.1016/j.nano.2014.04.003
Giaccia A (1998) Cancer therapy and tumor physiology. Science 279:10–15. https://doi.org/10.1126/science.279.5347.10e
Glück S (2014) Nab-paclitaxel for the treatment of aggreticulo endothelial systemsive metastatic breast cancer. Clin Breast Cancer 14:221–227. https://doi.org/10.1016/j.clbc.2014.02.001
Greish K (2007) Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 15:457–464. https://doi.org/10.1080/10611860701539584
Heath J, Davis M (2008) Nanotechnology and cancer. Annu Rev Med 59:251–265. https://doi.org/10.1146/annurev.med.59.061506.185523
Hertzberg R, Caranfa M, Hecht S (1989) On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme—DNA complex. Biochemistry 28:4629–4638. https://doi.org/10.1021/bi00437a018
Householder K, DiPerna D, Chung E, Wohlleb G, Dhruv H, Berens M, Sirianni R (2015) Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma. Int J Pharm 479:374–380. https://doi.org/10.1016/j.ijpharm.2015.01.002
Jain R, Stylianopoulos T (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7:653–664. https://doi.org/10.1038/nrclinonc.2010.139
Jang D, Moon C, Oh E (2016) Improved tumor targeting and antitumor activity of camptothecin loaded solid lipid nanoparticles by pre-injection of blank solid lipid nanoparticles. Biomed Pharmacother 80:162–172. https://doi.org/10.1016/j.biopha.2016.03.018
Knežević N, Lin V (2013) A magnetic mesoporous silica nanoparticle-based drug delivery system for photosensitive cooperative treatment of cancer with a mesopore-capping agent and mesopore-loaded drug. Nanoscale 5:1544–1551. https://doi.org/10.1039/c2nr33417h
Lammers T, Kiessling F, Hennink W, Storm G (2012) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progreticulo endothelial systems. J Control Release 161:175–187. https://doi.org/10.1016/j.jconrel.2011.09.063
Liu L, Desai S, Li T, Mao Y, Sun M, Sim S (2000) Mechanism of action of camptothecin. Ann NY Acad Sci 922:1–10. https://doi.org/10.1111/j.1749-6632.2000.tb07020.x
Maeda H (1991) SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 6:181–202. https://doi.org/10.1016/0169-409x(91)90040-j
Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–284. https://doi.org/10.1016/s0168-3659(99)00248-5
Maeda H, Sawa T, Konno T (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74:47–61. https://doi.org/10.1016/s0168-3659(01)00309-1
Mansoori G, Mohazzabi P, McCormack P, Jabbari S (2007) Nanotechnology in cancer prevention, detection and treatment: bright future lies ahead. World Rev Sci Technol Sustain Dev 4:226–257. https://doi.org/10.1504/wrstsd.2007.013584
Mross K (2004) A phase I clinical and pharmacokinetic study of the camptothecin glycoconjugate, BAY 38-3441, as a daily infusion in patients with advanced solid tumors. Ann Oncol 15:1284–1294. https://doi.org/10.1093/annonc/mdh313
Muller R, Keck C (2004) Challenges and solutions for the delivery of biotech drugs—a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 113:151–170. https://doi.org/10.1016/j.jbiotec.2004.06.007
Muniesa C, Vicente V, Quesada M, Sáez-Atiénzar S, Blesa J, Abasolo I et al (2013) Glutathione-sensitive nanoplatform for monitored intracellular delivery and controlled release of camptothecin. RSC Adv 3:15121–15131. https://doi.org/10.1039/c3ra41404c
Omar R, Bardoogo Y, Corem-Salkmon E, Mizrahi B (2017) Amphiphilic star polyethylene glycol-camptothecin conjugates for intracellular targeting. J Control Release 257:76–83. https://doi.org/10.1016/j.jconrel.2016.09.025
Padhi S, Behera A (2020) Nanotechnology based targeting strategies for the delivery of camptothecin. In: Saneja A, Panda A, Lichtfouse E (eds) Sustainable agriculture reviews, vol 44. Springer, Berlin, pp 243–272. https://doi.org/10.1007/978-3-030-41842-7_7
Padhi S, Mirza M, Verma D, Khuroo T, Panda A, Talegaonkar S et al (2015) Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro behavior and tumor amelioration potential. Drug Deliv 23:2827–2837. https://doi.org/10.3109/10717544.2015.1105323
Padhi S, Kapoor R, Verma D, Panda A, Iqbal Z (2018) Formulation and optimization of topotecan nanoparticles: in vitro characterization, cytotoxicity, cellular uptake and pharmacokinetic outcomes. J Photochem Photobiol, B 183:222–232. https://doi.org/10.1016/j.jphotobiol.2018.04.022
Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2:751–760. https://doi.org/10.1038/nnano.2007.387
Ryan A, Squires S, Strutt H, Evans A, Johnson R (1994) Different fates of camptothecin-induced replication fork-associated double-strand DNA breaks in mammalian cells. Carcinogenesis 15:823–828. https://doi.org/10.1093/carcin/15.5.823
Saitoh H, Sparrow D, Shiomi T, Pu R, Nishimoto T, Mohun T, Dasso M (1998) UBC9p and the conjugation of SUMO-1 to RanGAP1 and RanBP2. Curr Biol 8:121–124. https://doi.org/10.1016/s0960-9822(98)70044-2
Shi J, Wu P, Jiang Z, Wei X (2014) Synthesis and tumor cell growth inhibitory activity of biotinylated annonaceous acetogenins. Eur J Med Chem 71:219–228. https://doi.org/10.1016/j.ejmech.2013.11.012
Sinha R (2006) Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 5:1909–1917. https://doi.org/10.1158/1535-7163.mct-06-0141
Tang D, Song F, Chen C, Wang X, Wang Y (2013) A pH-reticulo endothelial systemponsive chitosan-b-poly(p-dioxanone) nanocarrier: formation and efficient antitumor drug delivery. Nanotechnology 24:145101. https://doi.org/10.1088/0957-4484/24/14/145101
Wall M, Wani M, Cook C, Palmer K, McPhail A, Sim G (1966) Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88:3888–3890. https://doi.org/10.1021/ja00968a057
Wu J, Liu L (1997) Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Nucleic Acids Reticuloendothel Syst 25:4181–4186. https://doi.org/10.1093/nar/25.21.4181
Yamauchi T, Yoshida A, Ueda T (2011) Camptothecin induces DNA strand breaks and is cytotoxic in stimulated normal lymphocytes. Oncol Rep 25:347–352. https://doi.org/10.3892/or.2010.1100
Yellepeddi V, Vangara K, Palakurthi S (2013) Poly (amido) amine (PAMAM) dendrimer–cisplatin complexes for chemotherapy of cisplatin-reticulo endothelial systemistant ovarian cancer cells. J Nanopart Reticuloendothel Syst 15:1897. https://doi.org/10.1007/s11051-013-1897-6
Zhang S (2017) Cancer therapy with co-delivery of camptothecin. J Drug Deliv Ther 7:76–79. https://doi.org/10.22270/jddt.v7i3.1450
Zhou Z, Piao Y, Hao L, Wang G, Zhou Z, Shen Y (2019) Acidity-reticulo endothelial systemponsive shell-sheddable camptothecin-based nanofibers for carrier-free cancer drug delivery. Nanoscale 11:15907–15916. https://doi.org/10.1039/c9nr03872h
Zi C, Yang L, Xu F, Dong F, Ma R, Li Y et al (2019) Synthesis and antitumor activity of biotinylated camptothecin derivatives as potent cytotoxic agents. Bioorg Med Chem Lett 29:234–237. https://doi.org/10.1016/j.bmcl.2018.11.049
Zunino F, Dallavalle S, Laccabue D, Beretta G, Merlini L, Pratesi G (2002) Current status and perspectives in the development of camptothecins. Curr Pharm Des 8:2505–2520. https://doi.org/10.2174/1381612023392801
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Behera, A., Padhi, S. Passive and active targeting strategies for the delivery of the camptothecin anticancer drug: a review. Environ Chem Lett 18, 1557–1567 (2020). https://doi.org/10.1007/s10311-020-01022-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10311-020-01022-9